Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

First Estimates of Health Outcomes for Patients with Hematologic Cancers and COVID-19

Web Exclusives

Late 2019 marked the first appearance of the SARS-CoV-2 coronavirus, which triggered a global pandemic of the disease commonly known as COVID-19. Because COVID-19 is a new disease, its effects on patients with hematologic cancers (those of the blood, bone marrow, and lymph nodes) are not well understood.

In systematic reviews and analyses of scientific publications, researchers searched for reports of patients with both hematologic cancers and COVID-19. Their primary goal was to determine whether patients with hematologic cancers had a greater risk of death associated with COVID-19, but they also tried to estimate how many patients needed to be admitted to the intensive care unit (ICU), how many needed mechanical ventilation, and how many of those who were admitted to the hospital needed noninvasive breathing support. The risks of death were further analyzed by patient age, treatment status, and precise type of cancer.

Overall, 29 published studies were identified, which included 25 studies in adults and 4 studies in children. Together, these studies included a total of 1847 patients from China, Europe, the United Kingdom, and North America who were found to have both a hematologic cancer and COVID-19.

Most of these patients (83%) were found to have required hospitalization for their illness. Approximately 1 in every 4 adult patients (23%) who were hospitalized required ICU admission. One in 6 patients (16%) required mechanical ventilation and an equal number required noninvasive breathing support.

More than 1 of every 3 patients (36%) with a hematologic cancer and COVID-19 died, with the risk of death being slightly higher (40%) for those who needed to be hospitalized. When grouped by age, patients who were aged ≥60 years had a much higher risk of death (46%) than patients aged <60 years (26%). Children in this analysis were found to have the lowest risk of death at 4%.

All types of hematologic cancer were found to have high risks of death when patients also developed COVID-19. Rates ranged from 31% for patients with chronic lymphocytic leukemia to 57% for patients with acquired bone marrow dysfunction syndromes such as acquired aplastic anemia. Notably, having recent cancer treatment did not significantly affect the risks of dying in this analysis.

These data provide some of the first estimates of the risk of death for patients with both hematologic cancers and COVID-19 and highlight the continued need for protecting these patients from contracting COVID-19.


Reference

Vijenthira A, Gong I, Fox TA, et al. Outcomes of adult and pediatric patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 1847 patients. Presented at the 62nd American Society for Hematology Annual Meeting and Exposition; December 7, 2020. Abstract 745.

Recommended For You